Bayer and Detroit-based Henry Ford Health announced a clinical trials partnership designed to connect more patients with investigational medicines, positioning Henry Ford as one of just four US academic health systems selected for Bayer’s strategic research network. The tie-up spans cardiovascular and renal disease, oncology and women’s health — three areas central to Bayer’s current pipeline — and reflects a broader industry shift toward embedding drug developers directly within health systems that serve large, diverse patient populations. Financial terms were not disclosed, and no specific drug candidate, technology platform or clinical trial identifier was named in the announcement.
Under the agreement, Bayer will combine its clinical development capabilities with Henry Ford Health’s trial infrastructure, electronic health record data and patient population to improve trial design, identify eligible participants and generate real-world evidence. The companies also plan to collaborate on data science training. No specific investigational therapies or clinical studies were disclosed.
The Henry Ford agreement is the second of its kind for Bayer within two weeks. On July 7, Bayer formed its first-ever academic medical center alliance with the University of Colorado Anschutz, UCHealth and Children’s Hospital Colorado, covering a similar mix of therapeutic areas along with neurodegenerative disease and cell and gene therapy. That deal marked Bayer’s first structured academic health system research network, and the Henry Ford partnership confirms the company is now executing a repeatable model rather than a one-off collaboration. With two of four planned network partners now named, Bayer appears to be assembling a distributed clinical trial infrastructure that spans multiple US regions and patient populations, though the identities of the remaining two systems have not been disclosed.